{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T23:53:50Z","timestamp":1777420430154,"version":"3.51.4"},"reference-count":34,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T00:00:00Z","timestamp":1748908800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ann Pharmacother"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To review the efficacy and safety of gepotidacin for the treatment of uncomplicated urinary tract infections (uUTIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Sources:<\/jats:title>\n                    <jats:p>A literature search was performed using PubMed and Google Scholar (both January 2010 to March 2025) with the search terms gepotidacin and GSK2140944. Other resources included conference abstracts, the manufacturer\u2019s web site, and prescribing information.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Study Selection and Data Extraction:<\/jats:title>\n                    <jats:p>All relevant English-language studies assessing gepotidacin efficacy and safety for the treatment of uUTIs were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Data Synthesis:<\/jats:title>\n                    <jats:p>\n                      Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with a novel mechanism of action that is active against strains of\n                      <jats:italic toggle=\"yes\">Escherichia coli<\/jats:italic>\n                      resistant to other classes of antibiotics, including the fluoroquinolones. Gepotidacin was non-inferior to nitrofurantoin in the treatment of healthy, non-pregnant females aged 12 years and older with uUTIs. Gastrointestinal effects are the most common adverse effects, and it has several potential drug-drug interactions. Relevance to Patient Care and Clinical Practice in Comparison to Existing Drugs Gepotidacin has been directly compared to nitrofurantoin for the treatment of uUTIs, but not to other commonly used drugs, such as trimethoprim\/sulfamethoxazole, fosfomycin, beta-lactams, and fluoroquinolones. However, it may be active against organisms resistant to these traditionally used agents due to its novel mechanism of action, making it an attractive option for patients with UTIs due to multidrug-resistant organisms. It should be administered with food to help decrease gastrointestinal-related adverse effects.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Gepotidacin is an antibiotic with a novel mechanism of action that is efficacious in the treatment of women with uUTIs caused by common uropathogens, including resistant strains.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10600280251343682","type":"journal-article","created":{"date-parts":[[2025,6,3]],"date-time":"2025-06-03T22:18:03Z","timestamp":1748989083000},"page":"66-75","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":5,"title":["Gepotidacin: A Novel Antibiotic for the Treatment of Uncomplicated Urinary Tract Infections"],"prefix":"10.1177","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6448-3879","authenticated-orcid":false,"given":"Spencer H.","family":"Durham","sequence":"first","affiliation":[{"name":"Auburn University Harrison College of Pharmacy, Huntsville, AL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1775-9497","authenticated-orcid":false,"given":"Elias B.","family":"Chahine","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice and Administration, Gregory School of Pharmacy, Palm Beach Atlantic University, West Palm Beach, FL, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,6,3]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1177\/1756287219832172"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciq257"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pop.2018.05.005"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw159"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-014-0659-4"},{"key":"e_1_3_2_7_2","unstructured":"U.S Food Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Published March 8 2018. Accessed March 28 2025. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-fda-updates-warnings-oral-and-injectable-fluoroquinolone-antibiotics"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq298"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.4140\/TCP.n.2016.381"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.3627"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280241288554"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2019.1680052"},{"key":"e_1_3_2_13_2","unstructured":"GlaxoSmithKline. Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older. Published March 25 2025. Accessed March 26 2025. https:\/\/www.gsk.com\/en-gb\/media\/press-releases\/blujepa-gepotidacin-approved-by-us-fda-for-treatment-of-uncomplicated-urinary-tract-infections\/"},{"key":"e_1_3_2_14_2","unstructured":"Blujepa. Prescribing information. GlaxoSmithKline 2025. Accessed March 26 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/218230s000lbl.pdf"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.8b00315"},{"issue":"0178","key":"e_1_3_2_16_2","first-page":"23","article-title":"Biochemical and genetic evidence that gepotidacin demonstrates well-balanced dual targeting against DNA gyrase and topoisomerase IV in Escherichia coli","volume":"2022","author":"Oviatt A","year":"2022","unstructured":"Oviatt A, Huang J, Ingraham K, Chan P, Osheroff N. Biochemical and genetic evidence that gepotidacin demonstrates well-balanced dual targeting against DNA gyrase and topoisomerase IV in Escherichia coli. Eur Cong Clin Microbiol Infect Dis. 2022;2022(L0178):23-26","journal-title":"Eur Cong Clin Microbiol Infect Dis"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature09197"},{"key":"e_1_3_2_18_2","volume-title":"Fifty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, AbstractF-1216;","author":"Bouchillon S","unstructured":"Bouchillon S, Hackel M, Miller LA, et al. In vitro activity of GSK2140944, a novel topoisomerase inhibitor, against isolates associated with lower respiratory tract and skin infections. Fifty-Third Interscience Conference on Antimicrobial Agents and Chemotherapy, AbstractF-1216; September 2013; Denver, CO."},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02820-15"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01263-21"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.807"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.913"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02385-16"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00468-17"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac406"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01525-22"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2021.115484"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00199-20"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12866-021-02245-8"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02196-7"},{"key":"e_1_3_2_31_2","unstructured":"U.S. Food and Drug Administration. Uncomplicated urinary tract infections: developing drugs for treatment guidance for industry. Published August 2019. Accessed February 22 2025. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/uncomplicated-urinary-tract-infections-developing-drugs-treatment-guidance-industry"},{"key":"e_1_3_2_32_2","unstructured":"European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Published December 2022. Accessed February 22 2025. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-medicinal-products-indicated-treatment-bacterial-infections-revision-3_en.pdf"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02697-1"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae403"},{"key":"e_1_3_2_35_2","unstructured":"Orylnvah. Prescribing information. Iterum Therapeutics 2024. Accessed March 27 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/213972s000lbl.pdf"}],"container-title":["Annals of Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251343682","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10600280251343682","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10600280251343682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T11:14:09Z","timestamp":1777374849000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10600280251343682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,3]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1177\/10600280251343682"],"URL":"https:\/\/doi.org\/10.1177\/10600280251343682","relation":{},"ISSN":["1060-0280","1542-6270"],"issn-type":[{"value":"1060-0280","type":"print"},{"value":"1542-6270","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,3]]}}}